5 NF-κB and AKT signaling prevent DNA damage by suppressing RAG1/2 | 137 40. Igarashi H, Baba Y, Nagai Y, Jimi E, Ghosh S, Kincade PW. NF-kappaB is dispensable for normal lymphocyte development in bone marrow but required for protection of progenitors from TNFalpha. Int Immunol. 2006; 18(5):653-659. 41. Cadera EJ, Wan F, Amin RH, Nolla H, Lenardo MJ, Schlissel MS. NF-kappaB activity marks cells engaged in receptor editing. J Exp Med. 2009;206(8):1803–1816. 42. Derudder E, Cadera EJ, Vahl JC, et al. Development of immunoglobulin lambda-chain positive B cells, but not editing of immunoglobulin kappa-chain, depends on NF-kappaB signals. Nat Immunol. 2009;10(6):647654. 43. Verkoczy L, Aït-Azzouzene D, Skog P, et al. A role for nuclear factor kappa B/rel transcription factors in the regulation of the recombinase activator genes. Immunity. 2005;22(4): 519-531. 44. Balkhi MY, Willette-Brown J, Zhu F, et al. IKKa-mediated signaling circuitry regulates early B lymphopoiesis during hematopoiesis. Blood. 2012;119(23):5467-5477. 45. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol. 1999;19(4):2690-2698. 46. Li J, Joo SH, Tsai M-D. An NF-kappaB-specific inhibitor, IkappaBalpha, binds to and inhibits cyclin-dependent kinase 4. Biochemistry. 2003;42(46):13476–13483. 47. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev. 1998;12(7):968981. 48. Chen F, Castranova V. Nuclear factor-kappaB, an unappreciated tumor suppressor. Cancer Res. 2007;67(23):11093-11098. 49. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153-166. 50. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014;13(2):140-156. 51. Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G. Targeting NF-kappaB in hematologic malignancies. Cell Death Differ. 2006;13(5):748-758. 52. Lim K-H, Yang Y, Staudt LM. Pathogenetic importance and therapeutic implications of NF-kB in lymphoid malignancies. Immunol Rev. 2012; 246(1):359-378.
RkJQdWJsaXNoZXIy MTk4NDMw